ClinicalTrials.gg
Active, not recruitingNCT05621369Updated Jun 1, 2026

Psorcast Mobile Study

An observational study in Psoriatic Arthritis, Psoriasis and Psoriatic Conditions, sponsored by Sage Bionetworks. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Sage Bionetworks · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Planned enrollment
11th of 34
1,000 · median 325
Started
2022
with 10 others
Observational
35 of 194
11 open now
Primary completion
2027-01
later than 21 of 59 live
Registered
147th of 194
by date

Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 11th largest by planned enrollment of the 34 observational ones that give a count, is one of 11 that started in 2022, is one of 35 observational ones, reaches primary completion later than 21 of the 59 other live ones, and was the 147th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.

Read the detailed description

Psoriatic disease exhibits a spectrum of symptoms and can transition from psoriasis (PsO), largely affecting the skin, to psoriatic arthritis (PsA) involving widespread musculoskeletal inflammation. Early detection of the PsO-to-PsA transition and rapid administration of effective treatment is essential, as a delay in diagnosing PsA by as little as 6 months can lead to irreversible joint damage. This "ticking clock" paradigm drives the need for frequent monitoring and effective therapeutic intervention as early as possible to attenuate or possibly prevent disease progression. Using a suite of smartphone-based measurements in an app called Psorcast (psoriasis forecasts), we aim to aggregate weekly, symptom measurements from participants in a remote, longitudinal observational study to map the trajectories of treatment response and disease progression. In this study, we will explore measurements of psoriatic disease activity at least an order of magnitude more frequently (weekly vs. quarterly) than standard clinical practice or clinical trial designs. This study is not meant to provide a medical diagnosis, treatment, or medical advice. It is meant to provide a scalable, inexpensive, non-invasive and frequent measure and tracking of psoriasis and psoriatic arthritis for research purposes.

03

Conditions studied

  • Psoriatic Arthritis
  • Psoriasis
  • Psoriatic Conditions
  • Dermatologic Disease
  • Rheumatologic Disease
  • Psoriatic Nail
  • Plaque Psoriasis
  • Joint Pain
  • Dactylitis

Keywords

  • Psoriasis
  • Psoriatic Arthritis
  • Psoriatic Disease
  • Health app research
  • mHealth research
  • Mobile health research
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults with a compatible iPhone or iPod Touch who consent to particpate

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult age 18 and older who consent to participate in the study
  • Own a compatible iPhone or iPod Touch device running iOS 12.2 or above
  • Be able to read and understand an official language of the country of participation

Exclusion criteria

Exclusion Criteria:

  • Age 17 years or younger
  • Not a resident of the a country where the app is approved for use
  • Not have a personal (i.e., not shared) iPhone (4s or newer running iOS 8.0 or later)
  • Not be able to read and understand an official language of the country of participation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with Psoriasis

    People who report a diagnosis of Psoriasis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).

    Behavioral: Participant self-assessment surveys · Behavioral: Psoriasis Draw · Behavioral: Psoriasis Area Photo · Behavioral: Finger and Toe Photos · Behavioral: Digital Jar Open · Behavioral: 30 Second Walk · Other: Psorcast mobile application

  • Participants with Psoriatic Arthritis

    People who report a diagnosis of Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).

    Behavioral: Participant self-assessment surveys · Behavioral: Psoriasis Draw · Behavioral: Psoriasis Area Photo · Behavioral: Finger and Toe Photos · Behavioral: Digital Jar Open · Behavioral: 30 Second Walk · Other: Psorcast mobile application

  • Participants without Psoriasis or Psoriatic Arthritis

    People who report no prior diagnosis of Psoriasis or Psoriatic Arthritis. Participants are invited via the Psorcast mobile application to complete the following assessments: Participant self-assessment surveys, skin assessments (Psoriasis Area Draw and Psoriasis Area Photo) and musculoskeletal assessments (Finger/Toe Photos, Joint Count, Digital Jar Open, 30s Walk).

    Behavioral: Participant self-assessment surveys · Behavioral: Psoriasis Draw · Behavioral: Psoriasis Area Photo · Behavioral: Finger and Toe Photos · Behavioral: Digital Jar Open · Behavioral: 30 Second Walk · Other: Psorcast mobile application

Interventions

  • BehavioralParticipant self-assessment surveys

    At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.

  • BehavioralPsoriasis Draw

    Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.

  • BehavioralPsoriasis Area Photo

    Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.

  • BehavioralFinger and Toe Photos

    Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.

  • BehavioralDigital Jar Open

    Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.

  • Behavioral30 Second Walk

    Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.

  • OtherPsorcast mobile application

    Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.

06

What researchers measure

Primary outcomes

  1. Results of participant self-assessment surveys

    Results of participant self-assessment surveys will be analyzed using descriptive statistics. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

  2. Body surface area and location from the Psoriasis Draw assessment

    The investigators will quantify body surface area and psoriasis area hotspots across the cohort. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

  3. Computer vision features from Psoriasis Area Photo assessment

    The investigators apply visual processing and classifier algorithms to analyze the images from the Psoriasis Area Photo assessments. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

  4. Computer vision features from Finger/Toe Photos

    The investigators apply visual processing and classifier algorithms to segment nails and joints from hand and foot photos. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

  5. Gyroscope and accelerometer sensor measurements from Digital Jar Open assessment

    The investigators examine rotational features from gyroscope and accelerometer sensors. The investigators apply feature selection and classifier algorithms to analyze these data. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

  6. Gyroscope and accelerometer sensor measurements from 30-sec Walk assessment

    The investigators examine step-dependent and sequence-dependent features from gyroscope and accelerometer sensors. The investigators apply feature selection and classifier algorithms to analyze these data. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

  7. Quantification and distribution of self-reported painful joints

    The investigators will quantify the self-reported painful joints and, in particular, compare to measurements from the 30-sec Walk and Digital Jar Open to identify correlations. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. App usage data for assessment of participant engagement

    App usage data is used to gauge participant engagement throughout the study period. These results may also be compared with other intervention results.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 site
  • Sage Bionetworks
    Seattle, Washington 98109, United States
08

References and documents

Publications

  • DE Webster, RH Haberman, LM Perez Chada, M Tummalacherla, A Tediarjo, V Yadav, E Chaibub Neto, W MacDuffie, M DePhillips, E Sieg, S Catron, C Grant, W Francis, M Nguyen, M Yussuff, RL Castillo, D Yan, AL Neimann, SM Reddy, A Ogdie, A Kolivras, MR Kellen, LM Mangravite, SK Sieberts, L Omberg, JF Merola, JU Scher medRxiv 2022.04.13.22273676; doi: https://doi.org/10.1101/2022.04.13.22273676

Individual participant data

Plan to share: Yes — We will share the de-identified data from participants who opt-in to data sharing during enrollment and consent.

Supporting information: Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2027, 60 months after the start.

Of 77 non-industry observational studies under Arthritis, Psoriatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 20. This study's planned 60 months is above that.

Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2022
First posted
Nov 18, 2022
StartActual
Jan 1, 2022
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05621369
Lead sponsor
Sage Bionetworks
Responsible party
Sponsor
First posted
Nov 18, 2022
Start date
Jan 1, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Solveig Sieberts, Ph.D
principal investigator · Sage Bionetworks
Jose Scher, MD
principal investigator · NYU Langone Medical Center
Joseph Merola, MD, MMSc
principal investigator · Brigham and Women's Hospital & Harvard Medical School

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion